Tumor-Derived Extracellular Vesicles Suppress the Antigen-specific Immune Response via Toll-like Receptor 4

Michael R Olin¹*, Brian M Andersen², Zhengming Xiong¹, Rob L Shaver¹, Lynne Bemis³, Mark Sanders⁴

¹Department of Pediatrics, University of Minnesota, Minneapolis, USA
²Department of Neurology, New York-Presbyterian/Weill Cornell Medical Center, New York, USA
³Department of Biomedical sciences, University of Minnesota, Duluth, USA
⁴University Imaging Center, University of Minnesota, Minneapolis, USA

*Corresponding author: Michael R Olin, 3-136 CCRB, 2231 6th St SE, Minneapolis, MN 55405, USA. Tel: +16126263123; Fax: +16126243514; E-mail: olin0012@umn.edu

Citation: Olin MR, Andersen BM, Xiong Z, Shaver RL, Bemis L, et al. (2017) Tumor-Derived Extracellular Vesicles Suppress the Antigen-specific Immune Response via Toll-like Receptor 4. J Vaccines Immunol: JVII-111. DOI: 10.29011/2575-789X.000011

Received Date: 26 June, 2017; Accepted Date: 25 July, 2017; Published Date: 01 August, 2017

Abstract

Background: Progression to a productive immune response involves passing through immunological checkpoints that act as barriers to effective immunotherapy. Thus, as tumors exploit multiple immune suppressive factors to inactivate the immune system, treatments against cancer have often failed to fully overcome the complex interplay between the immune system and the immunosuppressive tumor microenvironment. Recently, interest in the immunosuppressive effects of tumor-secreted exosomes has increased. Exosomes, a Subset of Extracellular Vesicles (EVs), play a role in intercellular communication that may be immunologically detrimental to develop an anti-tumor response.

Aim of the Study: We sought to investigate the suppressive role of Tumor-Derived Extracellular Vesicles (tEVs) on the ability to mount an antigen-specific response in vivo.

Study Design: To accomplish our objective, wildtype, Toll-Like Receptor 4 (TLR4) and Caspase-1 (Cas-1) Knockout (KO) mice were inoculated with tEVs isolated from gliomas.

Results: We show here that tEVs inhibit in vivo the antigen-specific immune response through TLR4. These results appear to be tumor-specific as non-tumor derived EVs failed to induce an anti-tumor response or TBM. Moreover, tEVs induce a population of suppressive Tingible-Body Macrophages (TBM) within the germinal centers of lymph nodes via the TLR4/Cas-1 axis. In addition, we determined that removal of Cas-1 pathway allows for tumor control indicating that inflammasome inhibit an anti-tumor response.

Conclusion: Tumor-derived EVs inhibit the ability to mount an anti-tumor response following immunotherapy, which may represent an important immune escape mechanism.
Keywords: Extracellular Vesicles; Immunotherapy; Inflammasomes; Toll-Like Receptors; Tumor-Derived Exosomes

Introduction

Increasing evidence indicates that the release and uptake of Extracellular Vesicles (EVs) is a crucial mode of cell-to-cell communication within tumors and the microenvironment. EVs are divided into three main subsets, i.e., apoptotic bodies, exosomes, and microvesicles, ranging from 30 to 2,000 nm in diameter. Unlike EVs derived from non-tumor cells, Tumor-Derived EV (tEVs) are enriched for tumor antigens such as melan-A and carcinoembryonic antigen [1,2], which are targets for immunotherapy [3]. However, despite preclinical and clinical data suggesting that tEVs are a rich source of tumor antigens, there is increasing evidence that they suppress antigen-specific and non-specific anti-tumor responses [4-9].

Tumor-derived EVs exert a broad array of detrimental effects on the immune system [10-12], particularly in gliomas [4]. EVs released by tumor cells contribute to angiogenesis [13], drug resistance [14], cell migration [15], and tumor progression by suppressing the immune system [16]. Studies have reported that multiple tumors block the differentiation of murine myeloid precursor cells into dendritic cells [17], carries TGF-β1, and skews IL-2 responsiveness in favor of regulatory T cells and away from cytotoxic cells [18]. Hsp72 on tEVs promotes The Immunosuppressive Activity of Myeloid Derived Suppressor cells (MDSC) via autocrine activation of the IL-6/STAT3 pathway [19]. Prostate cancer-derived tEVs downregulate NKG2D expression on Natural Killer (NK) and CD8¹ T cells, leading to impairment of their cytotoxic function [20,21] demonstrated that different concentrations of glioma-derived EVs have distinct effects on immune activation in vitro [4], as high concentrations of tEVs inhibited IFN production and proliferation [4].

Toll-like receptors have been reported to be immunosuppressive. TLR4 signaling induces the differentiation of T regulatory cells [22,23] and only TLR that activates both Myeloid Differentiation primary response 88 (MyD88), which is initiates downstream signaling that results in NF-κB activation and induction of proinflammatory mediators such as TNF-α and IL-6 [23]. However, TLR4 is also associated with inflammasomes, which are multimolecular complexes containing a caspase recruitment domain (ASC) and Caspase-1 (Cas-1). These complexes are responsible for the cleavage of pro-IL-1β and pro-IL-18 proteins into their active forms [24]. Although the function of inflammasomes in tumor growth and metastasis remains controversial, studies have indicated that increased concentrations of IL-1β protein are associated with poor prognosis for cancer patients [25,26]. Published colon cancer studies demonstrate that inflammasome components provide protection against tumorigenesis in colitis-associated colon cancer. However, mice deficient in inflammasomes, such as NLRP3, NLRP12, NLRC4 and Cas-1, have increased tumorigenesis in colon cancer animal model [27,28]. In addition, inflammasomes and IL-1β have been shown to enhance tumor growth in other cancers, including melanoma and mesothelioma [29]. Here, we show in vivo that tEVs specifically inhibit the antigen-specific immune response through TLR4. We also demonstrate that tEV-induced a suppressive macrophage population, The Tingible Body Macrophages (TBM), which was upregulated in wildtype mice but not in TLR4 or Cas-1 knockout mice.

Materials and Methods

Cell Lines and Culture

SIINFEKL and luciferin/-GFP expressing GL261 cells [30] and primary human glioblastoma cells obtained from patients were cultured in DMEM/F12 (1:1) supplemented with L-glutamine, sodium bicarbonate, penicillin/streptomycin (100 U/ml), B27 and N2 supplements, and 0.1-mg/ml normocin. Cultures were maintained in 5% CO₂ and supplemented semi-weekly with EGF and FGF, each at 20 ng/ml (R&D Systems, Mineapolis, MN) [31]. DC2.4, THP, and THP-ASC cell lines as well as primary murine lymphocytes were cultured in RPMI 1640 containing exosome-free fetal bovine serum. Murine transgenic OT-I cells were used to measure the OVA(SIINFEKL)-specific immune response. All cell lines were in house.

Preparation of Extracellular Vesicles

Extracellular vesicles were purified from GL261 or DC2.4 cell culture media using centrifugation at 5000 × g for 15 min. The supernatant was filtered using low-protein binding 0.22 μm pore filters. The filtered supernatants were separated by ultracentrifugation at 110,000 × g for 2 hr at 4°C using a Beckman Coulter Optima-XL ultracentrifuge and a 70Ti low-angle small volume fixed-angle rotor. The pelleted EVs were then washed with PBS and centrifuged again at 110,000 × g for 2 hr at 4°C. The resulting EVs were suspended in 0.5 mL PBS and stored at -80°C for later use. Purified EVs were then characterized by NanoSight, transmission electron microscopy (University of Minnesota Imaging Center), and flow cytometry as described by the manufacturer (System Bioscience, Palo Alto, CA), and submitted to System Bioscience for proteomic analysis.

Animal Models and Immunization

C57BL/6J and caspase-1 B6N.129S2-casp1fl/fl/j mice were purchased from Jackson Laboratories. B6.129T<sup>lps-del</sup>-Tlr4<sup>lps-del</sup> mice were a kind gift from Dr. Sabita Roy, University of Minnesota. OT-I mice were expanded in our laboratory. All mice were maintained in specific pathogen-free facilities at the University of Minnesota. Each animal study was reviewed and approved by the Institutional Animal Care and Use Committee at the University of Minnesota.
Mice underwent intradermal vaccination with tEV and OVA in the posterior neck for four consecutive days and once more on day 7 [32]. In selected experiments, mice received purified tEVs three days prior to vaccination. Treatment groups included: i) saline; ii) 100 μg ovalbumin (OVA (Fisher Bioreagents) plus 10 μg Poly: ICLC (Oncovir); or iii) 100 μg OVA plus 10 μg Poly: ICLC (Oncovir) and 50 μg EVs in a total volume of 100 μl.

### Intracranial inoculation

Mice were inoculated with 1.5x10⁴ GL261Luc+GFP+ cells in the right striatum at the following coordinates: 2.5 mm lateral and 0.5 mm anterior of bregma, and 3 mm deep from the cortical surface of the brain [30,33]. In selected experiments, C57BL/6J mice were implanted with ALZET pumps for a seven-day infusion of tEVs. The pump was placed at the same location as glioma cells for delivery.

### TLR activity:

HEK-Blue reporter cells stably express membrane-bound human TLR2 or human TLR4 and secrete alkaline phosphatase upon TLR stimulation (InvivoGen) as previously described [34]. HEK-Blue cells were pulsed with exosomes at different concentrations and incubated for 48 hrs. HEK-Blue cell supernatant was assayed for secreted embryonic alkaline phosphatase activity using QuantiBlue colorimetric enzyme assay (InvivoGen). Enzymatic activity was recorded as an increase in OD640 after being normalized to media-only treatment.

### Flow Cytometry:

A Becton Dickinson Canto three-laser flow cytometer was used for data acquisition. For whole blood staining, 50 μL whole blood was obtained via retro-orbital blood collection and placed in 100 μL of a 1:10 dilution of heparin in PBS. Five μL of the MHC Dextramer H-2 Kb/SIINFEKL (Immudex) was added to the blood. Following 10 min incubation at room temperature, 1 μL (0.5 mg) of anti-mouse CD8α-Pacific Blue (clone 53-6.7; eBioscience) was added to the cells that were incubated for an additional 20 min at room temperature. Red cells were lysed by adding 1 mL of a 1:10 lysis buffer dilution (BD Pharmigen), followed by 10 min incubation at room temperature, and centrifugation twice. Cell pellets were suspended in 100 μL PBS and analyzed by flow cytometry.

### Cytokine Production:

Mice were vaccinated as described above, lymphocytes were isolated from draining lymph nodes, and plated in RPMI 1640 media at a concentration of 4 x 10⁵ cells per well in 96-well plates. Lymphocytes were pulsed with 10 μg of the Dextramer H-2 Kb/SIINFEKL peptide, which contains the OVA-derived core epitope (EVSSLQLEQLESIINFEKLTEEWTSSNVM), for re-stimulation and incubated for 12 hr. Supernatants were analyzed for cytokine production using bead arrays (BD Bioscience).

### Anti-tumor Response:

These assays were conducted as previously described [33]. Draining lymph nodes were harvested and dissociated, and the resulting lymphocytes were incubated with CFSE-labeled GL261 cells for 4 hr at E: T ratios of 0:1, 25:1 and 50:1. Following incubation, cytotoxicity was analyzed according to the manufacturer’s protocol (Immunocytochemistry). Cell death was measured as the percentage of CFSE-labeled 7-AAD positive populations.

### Statistical Analysis

Statistical comparisons were made by ANOVA, followed by post-hoc comparisons using a two-tailed t-test. All tests were performed with the Prism 5 software (GraphPad Software, Inc). P values <0.05 were considered significant.

### Results

#### Characterization of Tumor-Derived Extracellular Vesicles

As tumors have been reported to secrete EVs [35], we isolated EVs derived from murine tumor cells (GL261) by ultracentrifugation [36], and characterized them by Transmission Electron Microscopy (TEM) (Supplementary Figure 1A) and NanoSight (Supplementary Figure 1B), and by flow cytometry for the common exosome markers, CD9 and CD63 [37] (Supplementary Figure 1C-D).

**Supplementary Figure 1:** Characterization of tumor-derived extracellular vesicles. Purified EVs were analyzed by (A) transmission electron microscopy and (B) NanoSight; Common EV markers (C) CD9 and (D) CD63 were assessed by flow cytometry.

The data showed that these preparations consisted of a mixture of exosomes (<100nm) and microvesicles (>100nm) [35, 38],...
which we will refer to as Tumor-Derived Extracellular Vesicles (tEVs) throughout the remainder of the manuscript.

Pre-Vaccinating with Tumor-Derived Extracellular Vesicles Suppresses the Antigen-Specific Immune Response

We hypothesized that tEVs may inhibit the ability to initiate an antigen immune response. Non-tumor bearing wildtype mice were vaccinated with OVA +/- tEVs as described in the Methods. Blood was isolated and analyzed for CD8-specific proliferation using the Dextramer H-2 Kb/SIINFEKL peptide. To our surprise, the antigen-specific proliferation was enhanced with the addition of tEVs to OVA (p=0.003; Figure 1A), but cytokine production was not changed (Figure 1B-D). Thus, the addition of tEVs did not significantly alter the immune response when administered with the antigen. However, as tEVs are theoretically secreted by tumors before any treatment by immunotherapy, we pre-treated mice with GL261-derived tEVs prior to vaccination then again with the antigen OVA. In these experiments, mice pretreated with tEVs significantly suppressed proliferation of OVA-specific CD8+ cells (p=0.0004; Figure 1A; black bar). Same decrease of OVA-specific CD8+ cells isolated from draining lymph nodes was observed (data not shown). In addition, pretreating mice with tEVs decreased the production of TNFα (p=0.001), IL-2 (p=0.0001) and IFN-γ (p=0.006) in response to OVA (Figure 1B-D; black bar). In contrast, we did not observe any immune suppression following inoculation with EVs prepared from non-tumor cells (DC2.4 cells) as assessed by antigen-specific expansion (Figure 1E) or IFN-γ response (Figure 1F), demonstrating that the immune suppression is specific to tEVs. Finally, to investigate the effects of tEVs on the development of an anti-tumor immune response, lymphocytes isolated from draining lymph nodes were restimulated with OVA-expressing GL261 cells (Figure 2). We concluded that pretreating mice with tEVs failed to mount an anti-tumor response to OVA-expressing glioma cells (p=0.001).

Figure 1: Pre-vaccinating with tumor-derived extracellular vesicles suppresses the antigen-specific immune response. Non-tumor bearing mice

![Figure 1](image1.png)

Figure 2: Tumor-derived extracellular vesicles suppress the cytolytic response. Lymphocytes were isolated from draining lymph nodes on day 8, stimulated with the SIINFEKL peptide, and incubated with OVA-transfected GL261 cells. The anti-tumor response was then analyzed by flow cytometry for a cytolytic response. Error bars are representative of standard deviation (n=5/group *P < 0.05 by t-test. Data represent the mean of three independent experiments).

Tumor-Derived Extracellular Vesicles Induce Tingible Body Macrophages

To explore the immunomodulatory effects of tEVs, draining (cervical) lymph nodes were harvested and H&E-stained. In contrast to mice treated with non-tumor-derived EVs (Figure 3A-B), mice inoculated with tEVs + OVA had well-defined germinal centers surrounded by thick marginal zones (Figure 3C-D). Interestingly, TUNEL staining of the germinal centers revealed the presence of apoptotic cells (Figure 3E-F). Given the observed immune suppression following the addition of tEVs, we hypothesized that the TUNEL positive cells could represent a small population of macrophages called tingible body macrophages (TBM). TBM are apoptotic macrophages residing in germinal centers that induce immune suppression through interactions with B cells and T helper cells [39]. To test our hypothesis, we stained the draining lymph nodes with antibodies to the macrophage markers, IBA-1 (Figure 3G) and CD3 (Figure 3H).
Figure 3: Tumor-derived extracellular vesicles induce tingible body macrophages. Mice were vaccinated with tumor-derived or non-tumor-derived EVs for three consecutive days, then vaccinated with OVA + tumor-derived or non-tumor derived EVs for 4 subsequent days and boosted on day 8 (A-D). On day 9, lymph nodes were harvested and H&E stained (E-F) or stained for TUNEL, IBA-1 (G), and IBA-1 + CD3 (H).

These experiments revealed that 13.6% of TBM interacted with CD3+ cells within a germinal center, potentially suppressing the immune response (Supplementary Figure 2A-F).

Supplementary Figure 2: Tingible body macrophages (TBM) are associated with CD3+ T cells. To quantitate the percentage of TBM associated with CD3+ cells within the germinal centers, a representative region from CD3+ (A) IBA-1- stained sections (B) were analyzed using Fiji/ImageJ. The images were aligned manually; (C-D) The CD3 and the IBA-1 images were color-deconvoluted using the Color Deconvolution plugin and the “H&E and DAB” setting. The CD3 brown image and IBA-1 magenta image was then thresholded manually, and both were post-processed by the morphological operator “Fill Holes” included in ImageJ; (E) area in yellow over area in green successively, the Manders coefficient was calculated using JACoP to find the percent of CD3+ regions overlapping the IBA-1+ regions; (F) The signals for IBA-1 and CD3 overlapped.

In our studies, mice were vaccinated with tEVs near the draining lymph nodes, resulting in the upregulation of the TUNEL-positive TBM. We previously reported that the sites of vaccination affect the strength of the CD8+ T cell response in the draining lymph nodes [30]. To ensure that our results were not an artifact of vaccination near the draining lymph nodes, ALZET pumps were mounted in non-tumor bearing mice to deliver tEVs at the same location/coordinates as the inoculation of tumor cells. The results showed that tEVs filtered from the entral nervous system to the draining lymph nodes and induced TBM (Supplementary Figure 3), supporting our previous findings that tEVs suppress the ability to mount an immune response.

Tumor-Derived Extracellular Vesicle-Induced Immune Suppression is TLR4-Mediated

Direct evidence indicates that anticancer drugs cause the release of exosomes from human hepatocellular carcinoma cells, and influence the release of Heat Shock Proteins (HSPs), modulating cells through Toll-like receptors [40]. Proteomics analysis of our tEV preparations demonstrated an increased expression of HSPs in tEVs compared to non-tumor derived EVs (Table 1).
Table 1: Heat shock protein detections. Tumor-derived and non-tumor derived extracellular vesicles were analyzed by proteomics. Heat shock protein are listed as numbers of protein detection.

| Protein | GL261 | DC2.4 |
|---------|-------|-------|
| HSP 70  | 27    | 0     |
| HSP 71  | 98    | 29    |
| HSP 90α | 132   | 9     |
| HSP 90β | 169   | 14    |
| HSP 105 | 10    | 0     |

Given that HSPs interact with Toll-Like Receptors (TLRs), we investigated the role of TLRs in the immunosuppression induced by tEVs. In these studies, different concentrations of tEVs were used to pulse TLR2- and TLR4-HEK293 cells transfected with an NFκB reporter to measure TLR signaling. We observed a dose-dependent increase in NFκB activity in both TLR2 (0-5 µg; p=0.04, 5-10 µg; p=0.002, 10-20 µg; p=0.001, 20-40 µg; p=0.04); (Figure 4A) and TLR4 (0-5 µg; p=0.0006, 5-10 µg; p=0.003, 10-20 µg; p=0.002, 20-40 µg; p=0.0004); (Figure 4B) cell lines pulsed with tEVs. In contrast, non-tumor derived EVs failed to activate NFκB (Figures. 4C-D). To further investigate the role of TLRs, TLR2 and TLR4 knockout mice were vaccinated with tEVs as described above. Tumor-derived EVs suppressed the induction of antigen-specific proliferation, measured as the percentage of SIINFEKL-specific CD8+ T cells, compared to wildtype mice receiving OVA only (OVA-WT; p=0.001 and OVA-TLR2; p=0.003); (Figure 4E). In addition, draining lymph nodes from TLR2 knockout mice had well-defined germinal centers containing TUNEL-positive T cells (Figure 4F). In contrast, tEVs failed to inhibit the induction of an immune response in TLR4 knockout mice (Figure 4E) and did not induce TUNEL- T cells (Figure 4G).
These results demonstrate that tEVs induce immune suppression through the TLR4 pathway.

**Tumor-Derived Extracellular Vesicles Signal Through the Inflammasome Pathway**

Our studies demonstrated that TUNEL-Positive Cells (TBM) are upregulated through TLR4. Thus, we further examined the activation of pathways parallel and downstream of TLR4, i.e., inflammasomes. In these experiments, Caspase-1 (Cas-1) Knockout (KO) mice were vaccinated with OVA + GL261-derived EVs. The results showed a lack of TUNEL+ cells in the germinal centers of lymph nodes (Figure 5B), as was seen in TLR4 KO mice. Because tEVs did not induce TBM in TLR4 and Cas-1 KO mice, we hypothesized that tumor growth would be reduced in these mice. To test our hypothesis, wildtype, TLR4 and Cas-1 KO mice were inoculated with GFP+ GL261 cells, and glioma-bearing mice were monitored for tumor growth and survival. Wildtype and TLR4 KO mice failed to reduce tumor growth (Figure 5D); however, after 14 days, tumor growth was reduced in Cas-1 KO mice (Figure 5C). Further analysis demonstrated that Cas-1 KO mice were able to totally eradicate the tumors from the CNS (Figure 5E). These results indicate that a TLR4-independent inflammasome pathway is involved in tumor growth. Interestingly, although tumors completely regressed, Cas-1 KO still died, albeit at a slower rate than WT or TLR4 KO (Figure 5F).

**Figure 5:** Tumor-derived extracellular vesicles signal through the inflammasome pathway. (A) The THP monocyte cell line and inflammasome KO THP-ASC were pulsed with tEVs. Mice were vaccinated with tEVs for three consecutive days, then vaccinated with OVA + tEVs and boosted on day 8; (B) On day 9, lymph nodes were harvested and TUNEL-stained; (C) Wildtype (WT), TLR4 and Caspase-1 (Cas-1) KO mice were inoculated with Luc’GFP+ GL261 cells and followed for tumor growth; on day 21, wildtype (D) and Cas-1 (E) knockout mice were euthanized and stained with GFP for tumor formation; (F) Another set of mice was followed for survival. Data are representative of four independent experiments; n=3/ treatment group.

**Discussion**

Tumor-derived EVs are promising candidates for targeting glioma progression and facilitating effective immune strategies [41,42]. Previous work revealed a direct correlation between tumor grade and tEV release, indicating that more aggressive tumors release more tEVs [2,43,44]. The highly malignant nature of gliomas and the high concentrations of circulating tEVs found in patients with other highly aggressive tumor types [43,45] suggest an important role of tEVs in promoting tumor progression and evading immune surveillance. Our data add to this narrative by demonstrating in vivo that glioma-derived EVs, and not non-tumor-derived EVs, suppress the antigen-specific immune response via activation of TLR4 and induction of Tingible Body Macrophages (TBM). Proteomic analysis of our EV preparations showed high levels of HSP71 and HSP90 in GL261-derived EVs compared to DC2.4-derived EVs (Table 1), suggesting that the high level of HSPs within EVs may stimulate TLRs. Indeed, *in vitro* studies with TLR2 and TLR4 cells transfected with an NFκB reporter showed that tEVs can activate both TLR2 and TLR4. However, when inoculating TLR2 and TLR4 KO mice with tEVs, the antigen-specific response, as measured by the percentages of SIINFEKL-specific CD8+ T cells, was suppressed in wildtype and TLR2 KO mice, but not in TLR4 KO mice, suggesting that only TLR4 is involved in the immunosuppressive mechanism triggered by tEVs.

We also showed that mice inoculated with tEVs + OVA specifically induced the suppressive TBM in the draining lymph nodes, as shown by the presence of the macrophage markers IBA-1 and CD3 in these TUNEL-positive cells. These data suggest that TBM may play a role in downregulating germinal center reaction, where they are predominantly located. This is supported by other studies reporting that TBM release prostaglandins, thereby reducing B-cell-mediated IL-2 production [39]. Interestingly, no TBM were detected in the TLR4-KO mice. Thus, we propose that TLR4 is activating TBM, which then suppress the immune response within the germinal centers through the secretion of prostaglandins, as was reported [39]. These findings may explain the current failure of immunotherapy drugs in central nervous system tumors. Further studies will be needed to confirm that glioma-derived EVs effectively produce prostaglandins. If confirmed, that may lead to the use of prostaglandin inhibitors such as Indomethacin with immunotherapy treatments to allow the immune system to better respond to tumor antigens. Accumulating data indicate that tumor development not only depends on genetic alterations, but also on the inflammatory microenvironment [46-49].
Innate pathways regulating the inflammatory response in the tumor microenvironment are not fully understood [24]. Among those, inflammasomes have increasingly gained interest. Inflammasomes are multi-molecular complexes containing a caspase recruitment domain (ASC) and Cas-1, and are responsible for the cleavage of pro-IL-1β and pro-IL-18 proteins into their active forms [24]. In our study, Cas-1 KO mice treated with glioma-derived EVs lacked TBM in the germinal centers, as observed in TLR4 KO mice, thus implicating a TLR4/Cas-1 axis in the activation of TBM. However, only the removal of Cas-1, and not that of TLR4, resulted in total regression of gliomas without the use of a tumor vaccine, suggesting that TLR4-independent inflammasomes may be involved in controlling tumor growth (Figures 5C, D). Interestingly, survival was only increased temporarily despite total glioma regression, which may have been related to cachexia.

These investigations demonstrate a new role for tumor-derived EVs in altering the immune response via TLR4 and inflammasomes. In addition, they also suggest that EVs secreted by tumors may be a factor in the inability of tumor-derived vaccines to elicit an adequate immune response.

Acknowledgments

We thank the following people for their technical assistance and critique of this work: Colleen Foster for IHC staining, James Xia for his laboratory assistants, and Craig Horbinski for his pathology assistance. We also like to thank Dr. Martine Torres for her critical review of the manuscript and editorial assistance. Dr. Olin and this work were supported by the National Cancer Institute R01CA154345 and the Randy Shaver Research and Community Fund. Dr. Andersen was supported by the Torske Klubben fellowship for Minnesota Residents, MSTP Grant T32 GM008244, Cancer Biology Training Grant T32 CA009138; 36, F30 CA16912-01A1.

References

1. Wolters J, Lozier A, Raposo G, Regnault A, Théry C, et al. (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nature medicine 7: 297-303.
2. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, et al. (2002) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305.
3. Andre F, Andersen M, Wolters J, Lozier A, Raposo G, et al. (2001) Exosomes in cancer immunotherapy: preclinical data. Adv Exp Med Biol 495: 349-354.
4. Hellwilkelnke J, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, et al. (2015) Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol 2015.
5. Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, et al. (2002) Induction of lymphocyte apoptosis by tumor cell secretion of Fas-L bearing microvesicles. J Exp Med 195: 1303-1316.
6. Huber V, Fais S, Iero M, Lugini L, Canese P, et al. (2005) Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 128: 1796-1804.
7. Klibi J, Nikl T, Riedel A, Pioche-Durieu C, Souquere S, et al. (2009) Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. Blood 113: 1957-1966.
8. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL (2003) T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 9: 5113-5119.
9. Schoery JS, Cheng Y, Singh PP, Smith VL (2015) Exosomes and other extracellular vesicles in host-pathogen interactions. EMBO Rep 16: 24-43.
10. Robbins PD and Morelli AE (2014) Regulation of immune responses by extracellular vesicles. Nat Rev Immunol 14: 195-208.
11. Whiteside TL (2013) Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41: 245-251.
12. Taylor DD and Gercel-Taylor C (2011) Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Seminars in immunopathology 33: 441-454.
13. Burke M, Chokasawangkarn W, Edwards N, Ostrand-Rosenberg S, Fenselau C (2014) Exosomes from myeloid-derived suppressor cells carry biologically active proteins. J Proteome Res 13: 836-843.
14. Chen WX, Cai YQ, Lv MM, et al. (2014) Exosomes from docetaxel-resistant breast cancer cells alter chemosensitivity by delivering microRNAs. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 35: 9649-9659.
15. Lazar I, Clement E, Ducoux-Petit M, Denat L3, Saldan V et al. (2015) Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines. Pigment Cell Melanoma Res 28: 464-475.
16. Valent R, Huber V, Iero M, Filippazi P, Parmiani G, et al. (2007) Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 67: 2912-2915.
17. Yu S, Liu C, Su K, Wang J, Liu Y, et al. (2007) Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 178: 6867-6875.
18. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z (2007) Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 67: 7458-7466.
19. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, et al. (2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 120: 457-471.
20. Lundholm M, Schroder M, Nagaeva O, Baranov V, Widmark A, et al. (2014) Prostate tumor-derived exosomes down-regulate NKKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One 9: e108925.
21. Wang J, Lu J, Lan Y, Zhou H, Li W, et al. (2013) Total coumarins from Urtica dentata Hand prevent murine autoimmune diabetes via suppression of the TLR4-signaling pathways. J Ethnopharmacol 146: 379-392.

22. Pasare C and Medzhitov R (2003) Toll-like receptors: balancing host resistance with immune tolerance. Current opinion in immunology 15: 677-682.

23. Barton GM and Medzhitov R (2003) Toll-like receptor signaling pathways. Science 300: 1524-1525.

24. Guo B, Fu S, Zhang J, Liu B, Li Z (2016) Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep 6: 36107.

25. Weber A, Wasiliw P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 2010.

26. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, et al. (2003) The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. International journal of oncology 23: 269-284.

27. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, et al. (2010) The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207: 1045-1056.

28. Allam R, Maillard MH, Tardivel A, Chennupati V, Bega H, et al. (2015) Epithelial NAIPs protect against colonic tumorigenesis. J Exp Med 212: 369-383.

29. Zitvogel L, Kepp O, Galluzzi L, Kroemer G (2012) Inflammasomes in carcinogenesis and anticancer immune responses. Nature immunology 13: 343-351.

30. Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, et al. (2013) Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol 190: 613-620.

31. Olin MR, Andersen BM, Litterman AJ, Grogan PT, Sarver RL, et al. (2011) Oxygen is a master regulator of the immunogenicity of primary human glioma cells. Cancer Res 71: 6583-6589.

32. Wick DA, Martin SD, Nelson BH, Webb JR (2011) Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 29: 984-993.

33. Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, et al. (2010) Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res 16: 4800-4808.

34. Andersen BM, Xia J, Epstein AL, Ohlfest JR4, Chen W, et al. (2016) Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant. J Immunother Cancer 4: 11.

35. Thakur A, Qiu G, Ng SP, Guan J, Yue J et al. (2017) Direct detection of two different tumor-derived extracellular vesicles by SAM-AuNIs LSPR biosensor. Biosens Bioelectron 94: 400-407.

36. Thery C, Amigorena S, Raposo G, Clayton A (2006) Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006.

37. Boing AN, van der Pol E, Grootemaat AE, Sturk A, Courmans FA, et al. (2014) Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles 2014: 3.

38. Gyorgy B, Szabo TG, Pasztai M, Pali Z, Misjak P, et al. (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cellular and molecular life sciences: CMLS 68: 2667-2688.

39. Smith J, Burton G, Tew J, Szakal AK (1998) Tingley Body Macrophages in Regulation of Germinal Center Reactions. Developmental Immunology 6: 285-294.

40. Lv LH, Wan YL, Lin Y, Zhang W, Yang M, et al. (2012) Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. The Journal of biological chemistry 287: 15874-15885.

41. Liu ZM, Wang YB, Yuan XH (2013) Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+ T cells. Asian Pac J Cancer Prev 14: 309-314.

42. Redzic JS, Ung TH, Graner MW (2014) Glioblastoma extracellular vesicles: reservoirs of potential biomarkers. Pharmgenomics Pers Med 7: 65-77.

43. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloeker GH (2009) Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 10: 42-46.

44. Taylor DD and Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 110: 13-21.

45. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, et al. (2014) Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC cancer 14: 176.

46. Hanahan D and Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.

47. Qian BZ and Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141: 39-51.

48. Joyce JA and Pollard JW (2009) Microenvironmental regulation of metastasis. Nature reviews Cancer 9: 239-252.

49. McAllister SS and Weinberg RA (2010) Tumor-host interactions: a far-reaching relationship. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 4022-4028.